Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.
Porter
J B
JB
Department of Haematology, University College London Medical School, UK.
Singh
S
S
Hoyes
K P
KP
Epemolu
O
O
Abeysinghe
R D
RD
Hider
R C
RC
D000818:Animals; D002460:Cell Line; D003676:Deferoxamine / Q000627:therapeutic use; D006168:Guinea Pigs; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity*; D051379:Mice; D011728:Pyridones / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity*; D051381:Rats; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured; D017086:beta-Thalassemia / Q000097:blood / Q000188:drug therapy
D007502:Iron Chelating Agents; D011728:Pyridones; C068543:1,2-diethyl-3-hydroxypyridin-4-one; D007501:Iron; D003676:Deferoxamine